Prediction of herb–drug interaction between hyperforin and sedative hypnotics (zolpidem, alprazolam, and midazolam) using physiologically-based pharmacokinetic modelingPrediction of herb–drug interaction between hyperforin and sedative hypnotics (zolpidem, alprazolam, and midazolam) using physiologically-based pharmacokinetic modeling
- Other Titles
- Prediction of herb–drug interaction between hyperforin and sedative hypnotics (zolpidem, alprazolam, and midazolam) using physiologically-based pharmacokinetic modeling
- Authors
- Shin, Anna; Jang, Boyun; Cho, Sunyoung; Kim, Youngsoo; Park, Min Soo; Park, Kwang-Il; Kim, Young Woo; Kim, Choon Ok
- Issue Date
- Feb-2024
- Publisher
- Springer Verlag
- Keywords
- Depression; Herb–drug interaction; Hyperforin; Physiologically based pharmacokinetic model
- Citation
- Molecular and Cellular Toxicology, v.20, no.2, pp 431 - 439
- Pages
- 9
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Molecular and Cellular Toxicology
- Volume
- 20
- Number
- 2
- Start Page
- 431
- End Page
- 439
- URI
- https://scholarworks.gnu.ac.kr/handle/sw.gnu/70041
- DOI
- 10.1007/s13273-024-00427-9
- ISSN
- 1738-642X
2092-8467
- Abstract
- Background: This study investigates the interactions between various doses of hyperforin, a key compound in St. John’s Wort, and sedative hypnotics such as zolpidem, alprazolam, and midazolam. Since St John’s Wort is known to be an inducer of cytochrome P450 (CYP) 3A4, co-administration with drugs metabolized by CYP3A4 has been contraindicated. Objective: We studied the risks of combination use and the possibility of safe combination by simulating the interaction of hyperforin, a key compound in St. John’s Wort, with drugs metabolized by CYP3A4 that can be used to relieve various symptoms of depression. Understanding these interactions is crucial for optimizing the treatment of depression and associated symptoms. Results: The hyperforin physiologically based pharmacokinetic (PBPK) model was validated against clinical data, and PBPK models for zolpidem, alprazolam, and midazolam were used to predict herb–drug interactions. The simulations with a two-week co-administration scenario showed that hyperforin potentially acts as a weak inducer (hyperforin dose 2–20 mg, 3 times a day, AUC ratio 0.8–0.68) of 10 mg zolpidem metabolism, with sex-dependent interactions largely unaffected. However, the pharmacokinetics of alprazolam at doses of 0.25, 0.5, and 1 mg were minimally impacted (hyperforin dose 1–20 mg, 3 times a day, AUC ratio 0.96–0.87). In the case of 7.5 mg midazolam, hyperforin acted as a moderate to strong inducer (hyperforin dose 1–20 mg, 3 times a day, AUC ratio 0.26–0.20), even at low doses. Conclusions: These findings emphasize the importance of careful monitoring and dose adjustments when using hyperforin and sedative hypnotics together. This study provided insights into co-administration of hyperforin and sedative hypnotics, facilitating the safe and effective use of these medications. Based on these results, it is necessary to know the possibility of safer drug combination, and to conduct clinical research and verification on this. © The Author(s) under exclusive licence to The Korean Society of Toxicogenomics and Toxicoproteomics 2024.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 수의과대학 > Department of Veterinary Medicine > Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.